The Internal Revenue Service has published final regulations that provide guidance on the annual fee imposed by the Affordable Care Act on covered entities engaged in the business of manufacturing or importing branded prescription drugs. The regulations describe the rules related to the fee, including how it is computed and how it is paid.
Branded Prescription Drug Fee
IRS Issues Notice on ACA Branded Prescription Drug Fee Parameters for 2013
The IRS has issued Notice 2012-74, which provides guidance on the ACA branded prescription drug (BPD) fee for the 2013 fee year. Specifically, the guidance addresses: (1) the submission of Form 8947, “Report of Branded Prescription Drug Information,” (2) the time and manner for notifying covered entities of their preliminary fee calculation, (3) the…
CMS Posts Information on Medicaid Data and the ACA Branded Prescription Drug Fee Program
CMS has developed a web page for information on the use of Medicaid data in the ACA Branded Prescription Drug Fee Program. By way of background, under the ACA, the Secretary of the Treasury determines the amount of the fee to be paid by each manufacturer according to the manufacturer’s share of branded prescription…
IRS Schedules Nov. 9, 2012 Hearing on ACA Branded Prescription Drug Fee
…
IRS Guidance on ACA Branded Prescription Drug Fee for 2012
This post was also written by Ruth Holzman.
The IRS has issued updated guidance to drug manufacturers on the Affordable Care Act’s annual fee imposed on covered entities engaged in the business of manufacturing or importing branded prescription drugs. The guidance addresses submission of required information, IRS notification of covered entities of their…